Tweet The sugestion is that they are all more or less the same. Here I think that this is good but one wonders when this will be a standard diagnostic test not run be a few labs. It should be a bog standard test. This depends on the access to the machines Dargvainiene J, Torge…
The medusa wins and Perseus is turned to primary progressive stone.
Tweet Tolebrutinib is a Brutons Tyrosine Kinase inhibitor and it failed to inhibit relapsing MS in trials compared to teriflunomide and now it has failed to inhibit progression in primary progressive MS in the PERSEUS trial…..so is there a future for tolebrutinib in non relapsing progressive MS? It has been approved in the Middle East…
Lipoic Acid 1-1..A positive and now a negative
Tweet Lipoic acid is the drug of hope in OCTOPUS trial because there was supportive evidence from trials in progressive MS in humans. However, this hope is being dashed by this recent trial. Lipoic acid wasn’t good enough in the trial, but was the trial good enough to show an effect of lipoic acid. This…
Let It Go Friday!
Happy Friday, y’all! I hope you have had a good week and you are ready for a weekend filled with what brings you the most happiness. It has been a while since I have written a post, as I have been very preoccupied. It is the week before Christmas, and I am still far from…
Highlighting the MS Community This Holiday Season and Always
As we approach the season of giving, the Multiple Sclerosis Association of America (MSAA) would like to bring special attention to the many wonderful community members that we serve. With our mission of Improving Lives Today, MSAA genuinely strives to … Continue reading → Source: blog.mymsaa.org
MS relapses peak in spring, summer as temperatures rise: Study
Relapses in people with relapsing-remitting multiple sclerosis (MS) may be more common in spring and summer, coinciding with warmer temperatures, low humidity, and greater fluctuations in atmospheric pressure, according to a study from Poland. Stressful life events and infections were the most frequent potential relapse triggers, the study found. “Better recognition of these issues within…
Battle of the High Efficacy Agents…Is anti-CD20 depletion the bee’s knees compared to migration inhibition?
Tweet This paper potentially hasn’t been peer-reviewed and looks at the differences between natalizumab and ocrelizumab and does a virutal head to head with the conclusion that anti-CD20 is more effective than natalizumab on disability progression and concludes that ocrelizumab is better….So is this bad news for the anti-CD49d. However, currently in Europe, ocrelizumab can…
Planning for life with MS means being willing to adapt
When I checked into the hospital last month, I answered all the usual diagnostic questions, but then one caught me off guard. A social worker asked if I had an advance directive in place. My first thought was to wonder just how bad the lab results were since I hadn’t seen them yet, but I…
Antioxidant lipoic acid slows brain atrophy in progressive MS: Study
In people with progressive multiple sclerosis (MS), treatment with the antioxidant lipoic acid did not improve walking or lessen other symptoms, such as fatigue, but it did show signs of slowing brain atrophy, or the loss of brain tissue. According to the researchers, this suggests possible positive biological effects from the antioxidant’s use, despite no…
Researchers identify enzyme as new target for MS myelin repair
An enzyme called CEMIP could be a target for small-molecule inhibitors that aim to promote myelin repair in people with multiple sclerosis (MS) and other conditions marked by myelin loss, a study found. Researchers discovered that CEMIP, which is elevated in areas of inflammatory nerve damage in people with MS, produces numerous hyaluronic acid molecules…